Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UroGen Pharma Ltd. Director's Dealing 2023

Jul 27, 2023

32312_dirs_2023-07-27_567b61f0-7afc-42db-9ed8-5d9d667f6ba3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2023-07-25

Reporting Person: Robinson James A. Jr. (Director)